轻度白蛋白尿是非糖尿病人群肾小球滤过率更快下降的危险因素
在非糖尿病、无心血管疾病和慢性肾脏病的中年人群中,基线尿白蛋白肌酐比(ACR)轻度升高与肾小球滤过率(GFR)下降速度更快独立相关。即使ACR处于目前认为的最佳范围(<1.13 mg/mmol),ACR 0.11-1.12 mg/mmol者较≤0.10 mg/mmol者GFR下降更快。
要点
- 非糖尿病人群中,ACR轻度升高即可预测GFR下降更快。
- ACR在最佳范围内(0.11-1.12 mg/mmol)仍与GFR下降加速相关。
- 白蛋白尿的肾脏风险阈值可能低于现行正常上限。
核心结论
- 在非糖尿病人群中,轻度升高的ACR是GFR更快下降的独立危险因素。
研究设计与样本
- 基于Renal Iohexol Clearance Survey队列,基线纳入1567例无糖尿病、心血管疾病和慢性肾脏病的中年人,ACR<3.40 mg/mmol(30.0 mg/g)。
- 采用碘海醇清除率测量GFR,中位随访5.6年后有1278例(81%)重复测量GFR。
主要发现
- 基线ACR中位数0.22 mg/mmol(四分位距0.10-0.51 mg/mmol),平均GFR 104.0±20.1 ml/min,平均GFR下降速率-0.95±2.23 ml/min/年。
- 多变量调整后,ACR 0.11-0.45 mg/mmol者较ACR≤0.10 mg/mmol者GFR下降快0.25 ml/min/年(95%CI -0.03至0.53)。
- ACR 0.46-3.40 mg/mmol者较ACR≤0.10 mg/mmol者GFR下降快0.31 ml/min/年(95%CI 0.02-0.60)。
- 在ACR<1.13 mg/mmol的最佳范围内,ACR 0.11-1.12 mg/mmol者(n=812)较ACR≤0.10 mg/mmol者(n=655)GFR下降快0.28 ml/min/年(95%CI 0.04-0.52)。
临床怎么用
- 在非糖尿病人群中评估肾脏风险时,应关注ACR的轻度升高,即使处于传统正常范围。
- 对于ACR在0.11 mg/mmol以上的非糖尿病患者,可考虑更密切监测GFR变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A minimal increase in the albumin-to-creatinine ratio (ACR) predicts cardiovascular disease and mortality, but whether it predicts kidney function loss in nondiabetic persons is unclear. We investigated the association between ACR in the optimal or high-normal range and the rate of glomerular filtration rate (GFR) decline in a cohort from the general population without diabetes, cardiovascular, or chronic kidney disease. METHODS: In the Renal Iohexol Clearance Survey, we measured GFR using iohexol clearance in 1567 middle-aged nondiabetic individuals with an ACR <3.40 mg/mmol (30.0 mg/g) at baseline. The ACR was measured in unfrozen morning urine samples collected on 3 days before the GFR measurements. A total of 1278 (81%) participants had follow-up with GFR measurements after a median of 5.6 years. RESULTS: The median ACR at baseline was 0.22 mg/mmol (interquartile range: 0.10-0.51 mg/mmol), the mean ± SD GFR was 104.0 ± 20.1 ml/min, and the mean ± SD GFR decline rate was -0.95 ± 2.23 ml/min per year. Higher baseline ACR levels were associated with a steeper GFR decline in adjusted linear mixed models. Study participants with ACR levels of 0.11 to 0.45 and 0.46 ± 3.40 mg/mmol had a 0.25 ml/min per year (95% confidence interval [95% CI]: -0.03 to 0.53) and 0.31 ml/min per year (95% CI: 0.02-0.60) steeper rate of decline than those with ACR ≤0.10 mg/mmol in multivariable-adjusted analyses. Among study participants with an ACR of <1.13 mg/mmol (defined as the optimal range), those with an ACR of 0.11 to 1.12 mg/mmol (n = 812) had a 0.28 ml/min per year (95% CI: 0.04-0.52) steeper rate of GFR decline than those with an ACR of ≤0.10 mg/mmol (n = 655). CONCLUSION: A mildly increased ACR is an independent risk factor for faster GFR decline in nondiabetic individuals.
引用
- Melsom T, Solbu MD, Schei J, et al. Mild Albuminuria Is a Risk Factor for Faster GFR Decline in the Nondiabetic Population. Kidney Int Rep. 2018. PMID: 29989017. doi:10.1016/j.ekir.2018.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。